A specific gene expression signature for visceral organ metastasis in breast cancer

被引:43
作者
Savci-Heijin, C. D. [1 ]
Halfwerk, H. [1 ]
Koster, J. [2 ]
Horlings, H. M. [3 ]
van de Vijver, M. J. [1 ]
机构
[1] Univ Amsterdam, Amsterdam UMC, Dept Pathol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Amsterdam UMC, Dept Oncogenom, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[3] Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands
关键词
Organotropism; Pathology; Site-specific relapse; Microarray; BONE METASTASIS; H+-ATPASE; SURVIVAL; LUNG; PROGRESSION; PREDICTOR; THERAPY; PH;
D O I
10.1186/s12885-019-5554-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Visceral organ metastasis is associated with poor survival outcomes in terms of metastasis free- and overall survival in breast carcinomas. Identification of a gene expression profile in tumours that selects a subpopulation of patients that is more likely to develop visceral organ metastases will help elucidate mechanisms for the development of distant metastases and could be of clinical value. With this study we aimed to determine genomic predictors that would help to distinguish breast cancer patients with more likelihood to develop visceral metastasis. Methods: Gene expression profiling data of 157 primary tumours from breast cancer patients who developed distant metastases were analyzed and differentially expressed genes between the group of tumours with visceral metastasis and the those without visceral metastases were identified. Published data were used to validate our findings. Multivariate logistic regression tests were applied to further investigate the association between the gene-expression-signature and clinical variables. Survival analyses were performed by the Kaplan-Meier method. Results: Fourteen differentially expressed genes (WDR6, CDYL, ATP6V0A4, CHAD, IDUA, MYL5, PREP, RTN4IP1, BTG2, TPRG1, ABHD14A, KIF18A, S100PBP and BEND3) were identified between the group of tumours with and without visceral metastatic disease. Five of these genes (CDYL, ATP6V0A4, PREP, RTN4IP1 and KIF18A) were up-regulated and the other genes were down-regulated. This gene expression signature was validated in the training and in the independent data set (p 2.13e-08 and p 9.68e- 06, respectively). Multivariate analyses revealed that the 14-gene-expression-signature was associated with visceral metastatic disease (p 0.001, 95% CI 1.43-4.27), independent of other clinicopathologic features. This signature has been also found to be associated with survival status of the patients (p < .001). Conclusion: We have identified an unique gene expression signature which is specific to visceral metastasis. This 14-gene-expression-signature may play a role in identifying the subgroup of patients with potential to develop visceral metastasis.
引用
收藏
页数:8
相关论文
共 34 条
  • [11] Up-regulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray
    Mollerstrom, Elin
    Kovacs, Aniko
    Lovgren, Kristina
    Nemes, Szilard
    Delle, Ulla
    Danielsson, Anna
    Parris, Toshima
    Brennan, Donal J.
    Jirstrom, Karin
    Karlsson, Per
    Helou, Khalil
    [J]. BMC CANCER, 2010, 10
  • [12] High-resolution genomic profiling to predict 10-year overall survival in node-negative breast cancer
    Mollerstrom, Elin
    Delle, Ulla
    Danielsson, Anna
    Parris, Toshima
    Olsson, Bjorn
    Karlsson, Per
    Helou, Khalil
    [J]. CANCER GENETICS AND CYTOGENETICS, 2010, 198 (02) : 79 - 89
  • [13] Nuyten Dimitry S A, 2006, Breast Dis, V26, P149
  • [14] Expression of 16 kDa proteolipid of vacuolar-type H+-ATPase in human pancreatic cancer
    Ohta, T
    Numata, M
    Yagishita, H
    Futagami, F
    Tsukioka, Y
    Kitagawa, H
    Kayahara, M
    Nagakawa, T
    Miyazaki, I
    Yamamoto, M
    Iseki, S
    Ohkuma, S
    [J]. BRITISH JOURNAL OF CANCER, 1996, 73 (12) : 1511 - 1517
  • [15] PAGET S, 1989, CANCER METAST REV, V8, P98
  • [16] A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Paik, S
    Shak, S
    Tang, G
    Kim, C
    Baker, J
    Cronin, M
    Baehner, FL
    Walker, MG
    Watson, D
    Park, T
    Hiller, W
    Fisher, ER
    Wickerham, DL
    Bryant, J
    Wolmark, N
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27) : 2817 - 2826
  • [17] Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
    Parker, Joel S.
    Mullins, Michael
    Cheang, Maggie C. U.
    Leung, Samuel
    Voduc, David
    Vickery, Tammi
    Davies, Sherri
    Fauron, Christiane
    He, Xiaping
    Hu, Zhiyuan
    Quackenbush, John F.
    Stijleman, Inge J.
    Palazzo, Juan
    Marron, J. S.
    Nobel, Andrew B.
    Mardis, Elaine
    Nielsen, Torsten O.
    Ellis, Matthew J.
    Perou, Charles M.
    Bernard, Philip S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) : 1160 - 1167
  • [18] A molecular signature of metastasis in primary solid tumors
    Ramaswamy, S
    Ross, KN
    Lander, ES
    Golub, TR
    [J]. NATURE GENETICS, 2003, 33 (01) : 49 - 54
  • [19] Vacuolar-type H+-ATPases at the plasma membrane regulate pH and cell migration in microvascular endothelial cells
    Rojas, J. D.
    Sennoune, S. R.
    Maiti, D.
    Bakunts, K.
    Reuveni, M.
    Sanka, S. C.
    Martinez, G. M.
    Seftor, E. A.
    Meininger, C. J.
    Wu, G.
    Wesson, D. E.
    Hendrix, M. J. C.
    Martinez-Zaguilan, R.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2006, 291 (03): : H1147 - H1157
  • [20] Breast carcinoma survival in Europe and the United States -: A population-based study
    Sant, M
    Allemani, C
    Berrino, F
    Coleman, MP
    Aareleid, T
    Chaplain, G
    Coebergh, JW
    Colonna, M
    Crosignani, P
    Danzon, A
    Federico, M
    Gafà, L
    Grosclaude, P
    Hédelin, G
    Macè-Lesech, J
    Garcia, CM
    Moller, H
    Paci, E
    Raverdy, N
    Tretarre, B
    Williams, EMI
    [J]. CANCER, 2004, 100 (04) : 715 - 722